Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Infection, Outcomes

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, SEPTEMBER 22, 2022

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2022.32760?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=092222

About JAMA Network Open: JAMA Network Open is the new online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

 

About The Study: This study estimated the effectiveness of COVID-19 vaccines against symptomatic infections due to the Delta and Omicron variants and severe outcomes (hospitalization or death) associated with these infections among adults in Ontario, Canada.

Authors: Jeffrey C. Kwong, M.D., of Public Health Ontario in Toronto, is the corresponding author.

 

(doi:10.1001/jamanetworkopen.2022.32760)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.